GNI Group Ltd. (FRA:3G6)

Germany flag Germany · Delayed Price · Currency is EUR
15.30
-0.20 (-1.29%)
Last updated: Feb 20, 2026, 8:06 AM CET
Market Cap872.60M -11.6%
Revenue (ttm)145.80M +13.7%
Net Income-23.96M
EPS-0.46
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open15.30
Previous Close15.50
Day's Range15.30 - 15.30
52-Week Range8.80 - 26.00
Betan/a
RSI65.29
Earnings DateFeb 13, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved i... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 867
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 3G6
Full Company Profile

Financial Performance

Financial numbers in JPY Financial Statements